Leukemia Clinical Trials in San Francisco

Showing 701-720 of 893 trials

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

NCT02406235

The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.

Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer

AstraZeneca710 participantsStarted Apr 2015

San Francisco, California, United States • Gainesville, Florida, United States • Sarasota, Florida, United States +23 more locations

COMPLETEDPhase 2< 1 mile

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

NCT00857545

This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has decreased or disappeared, but the cancer may still be in the body. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether OPT-821 is more effective with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Stage IA Fallopian Tube CancerStage IA Ovarian CancerStage IB Fallopian Tube Cancer+21 more

Gynecologic Oncology Group171 participantsStarted Jul 2010

Mobile, Alabama, United States • Orange, California, United States • Palo Alto, California, United States +43 more locations

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Leukemia Trials in Other Cities

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Functional Vision in TBI

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)

Other Conditions in San Francisco